- Home
- INTS vs AKTX Comparison
INTS vs AKTX Comparison
Compare INTS & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- AKTX
- Stock Information
- Founded
- INTS 2012
- AKTX N/A
- Country
- INTS United States
- AKTX United States
- Employees
- INTS N/A
- AKTX N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- AKTX Health Care
- Exchange
- INTS Nasdaq
- AKTX Nasdaq
- Market Cap
- INTS 9.4M
- AKTX 41.8M
- IPO Year
- INTS 2023
- AKTX N/A
- Fundamental
- Price
- INTS $0.32
- AKTX $1.17
- Analyst Decision
- INTS Strong Buy
- AKTX
- Analyst Count
- INTS 3
- AKTX 0
- Target Price
- INTS $8.50
- AKTX N/A
- AVG Volume (30 Days)
- INTS 2.6M
- AKTX 28.8K
- Earning Date
- INTS 08-07-2025
- AKTX 08-18-2025
- Dividend Yield
- INTS N/A
- AKTX N/A
- EPS Growth
- INTS N/A
- AKTX N/A
- EPS
- INTS N/A
- AKTX N/A
- Revenue
- INTS N/A
- AKTX N/A
- Revenue This Year
- INTS N/A
- AKTX N/A
- Revenue Next Year
- INTS N/A
- AKTX N/A
- P/E Ratio
- INTS N/A
- AKTX N/A
- Revenue Growth
- INTS N/A
- AKTX N/A
- 52 Week Low
- INTS $0.26
- AKTX $0.85
- 52 Week High
- INTS $5.10
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- INTS 37.08
- AKTX 44.98
- Support Level
- INTS $0.28
- AKTX $1.15
- Resistance Level
- INTS $0.32
- AKTX $1.22
- Average True Range (ATR)
- INTS 0.06
- AKTX 0.08
- MACD
- INTS 0.01
- AKTX -0.00
- Stochastic Oscillator
- INTS 7.43
- AKTX 40.86
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.